Icelandic
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Litak (cladribine) - L01BB04

Updated on site: 08-Oct-2017

Nafn lyfsLitak
ATC-kóðiL01BB04
Efnicladribine
FramleiðandiLipomed GmbH

Efnisyfirlit

LITAK

EPAR summary for the public

This document is a summary of the European Public Assessment Report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine.

If you need more information about your medical condition or your treatment, read the Package Leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the Scientific Discussion (also part of the EPAR).

What is Litak?

Litak is a solution for injection that contains the active substance cladribine.

What is Litak used for?

Litak is used to treat adults with hairy cell leukaemia, a cancer of blood in which too many B-lymphocytes (a type of white blood cell) are produced. The term ‘hairy cell’ refers to the hair-like projections that can be seen on the surface of the lymphocytes when they are examined under a microscope.

Because the number of patients with hairy cell leukaemia is low, the disease is considered ‘rare’, and Litak was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 18 September 2001. The medicine can only be obtained with a prescription.

Athugasemdir

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
  • Hjálp
  • Get it on Google Play
  • Um okkur
  • Info on site by:

  • Presented by RXed.eu

  • 27558

    skráð lyfseðilsskylt lyf